Caraco faces class action suit in the US
This article was originally published in Scrip
Executive Summary
Caraco Pharmaceutical Laboratories, currently under US FDA scrutiny for current good manufacturing practice (cGMP) lapses, faces a class action suit in the US for allegedly failing to make adequate disclosures during the regulatory probe. Caraco is a US subsidiary of India's Sun Pharmaceutical Industries.